Suppression of Antitumor Immunity by Stromal Cells Expressing Fibroblast Activation Protein–α

By Matthew Kraman, P. Bambrough, J. N. Arnold, Edward W. Roberts, Lukasz Magiera, James O. Jones, A. Gopinathan, D. Tuveson, D. Fearon. Science, 2010

1,021 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Tumor microenvironment complexity and therapeutic implications at a glance (2020, background): “In view of the critical role of CAFs in the design of TME, the therapeutic options for deactivating CAF-mediated interaction are largely focused on using/reprogramming or eliminating of CAFs [76] [77] [78] .”
Major Histocompatibility Complex Genomics and Human Disease (2013, neutral): “Viral escape from MHC class I presentation is important, and class I expression plays a role in cancer surveillance (8, 70).”
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy (2019, background): “FAP-specific CAR T cell FAP deletion Anti-tumor CAR T cell Enhances anti-tumor immunity Lung cancer Preclinical [116]”
Cancer-related inflammation: common themes and therapeutic opportunities. (2012, background): “When fibroblast activation protein, FAP- , expressing fibroblasts were depleted in tumor-bearing ice, rapid hypoxic necrosis of tumor and stromal cells occurred ccompanied by IFN- and TNF- -mediated CD8+ T cell cytotoxicty [24].”
Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. (2018, neutral): “In addition, CAFs have been shown to contribute to drug resistance (Straussman et al., 2012; Paulsson et al., 2017) and to reduce anti-tumor immunity (Kraman et al., 2010; Tan et al., 2011; Feig et al., 2013; Denton et al., 2014; Ruhland et al., 2016; Yang et al., 2016).”